MOUNTAIN VIEW, Calif.,
April 17, 2014 /PRNewswire/
-- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced today
that Winston R. Brown, Jr. has
joined the Company as Vice President, Quality. Mr. Brown
brings more than two decades of experience in global quality,
regulatory compliance and development operations working with
diverse biopharmaceuticals, medical devices and nutritionals in
globally integrated companies. In this position, Mr. Brown
has primary responsibility for Quality Assurance, Quality Control
and Quality Systems.
"With the ongoing commercialization of ADASUVE in the U.S. and
EU, and commercial collaborations in place with Teva and Ferrer, it
is an exciting time to join Alexza," said Mr. Brown. "I look
forward to working with Alexza's talented employees to continue the
transition from a development stage company to commercial stage
company."
"We are pleased to welcome Winston to our team," said
Robert A. Lippe, Executive Vice
President, Operations and Chief Operations Officer at
Alexza. "Winston brings extensive quality program expertise
coupled with strong operational leadership experience to our
company, at a time of exciting growth in both scale and
scope. We look forward to his contributions in support of our
efforts with the global ADASUVE launch and in expanding our
candidate pipeline."
From December 2011 to April 2014, Mr. Brown served as Global Head,
Quality R&D - Pharmaceuticals, Biologics, and Vision Care
Devices at Alcon Research, Ltd., a division of Novartis. Mr.
Brown was the Executive Director, Global Quality Compliance for
Baxter Healthcare International from November 2009 to December 2011. From
January 2008 to October 2009, Mr. Brown was with Bausch &
Lomb as its Director of Site Quality - Vision Care-Sterile
Ophthalmic Solutions. Mr. Brown previously held multiple
leadership positions in quality systems/compliance, regulatory
affairs, and process validation with Holopack Pharmaceuticals,
USA and J&J Consumer
Pharmaceuticals. Prior to entering the private healthcare
industry, Mr. Brown served as an Officer in the United States Army, where he held various
operational roles including Laboratory Officer in Clinical
Pathology at Walter Reed Army Medical Center. Mr. Brown holds
an M.S. degree in Pharmaceutical Engineering from Stevens Institute of Technology, an M.B.A. from
Cameron University - University of Oklahoma, a B.S. in Microbiology
& Operations Management from Concord
University and a Medical Technology degree from George Washington University.
About Alexza Pharmaceuticals, Inc.
Alexza Pharmaceuticals is focused on the research, development and
commercialization of novel, proprietary products for the acute
treatment of central nervous system conditions. Alexza's
products are based on the Staccato® system, a hand-held
inhaler designed to deliver a drug aerosol to the deep lung,
providing rapid systemic delivery and therapeutic onset, in a
simple, non-invasive manner.
ADASUVE is Alexza's first commercial product. It has been
approved for sale by the U.S. Food and Drug Administration and the
European Commission. Teva Pharmaceuticals USA, Inc. is Alexza's commercial partner for
ADASUVE in the U.S. Grupo Ferrer
Internacional, S.A. is Alexza's commercial partner for
ADASUVE in Europe, Latin America and the Commonwealth of
Independent States.
ADASUVE® and Staccato® are registered
trademarks of Alexza Pharmaceuticals, Inc.
Safe Harbor Statement
This news release contains
forward-looking statements that involve significant risks and
uncertainties. Any statement describing the Company's expectations
or beliefs is a forward-looking statement, as defined in the
Private Securities Litigation Reform Act of 1995, and should be
considered an at-risk statement. Such statements are subject to
certain risks and uncertainties, particularly those inherent in the
process of developing and commercializing drugs, including the
ability of Alexza and its partners, Teva and Ferrer, to effectively
and profitably commercialize ADASUVE, estimated product revenues
and royalties associated with the sale of ADASUVE, the adequacy of
the Company's capital to support the Company's operations, and the
Company's ability to raise additional funds and the potential terms
of such potential financings. The Company's forward-looking
statements also involve assumptions that, if they prove incorrect,
would cause its results to differ materially from those expressed
or implied by such forward-looking statements. These and other
risks concerning Alexza's business are described in additional
detail in the Company's Annual Report on Form 10-K for the year
ended December 31, 2013 and the
Company's other Periodic and Current Reports filed with the
Securities and Exchange Commission. Forward-looking statements
contained in this announcement are made as of this date, and the
Company undertakes no obligation to publicly update any
forward-looking statement, whether as a result of new information,
future events or otherwise.
Logo -
http://photos.prnewswire.com/prnh/20140121/SF49110LOGO
SOURCE Alexza Pharmaceuticals, Inc.